TETRAULT LYNN A. 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Sep 11, 2024
Insider Transaction Report
Form 4
TETRAULT LYNN A.
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2024-09-09−3,199→ 7,501 totalExercise: $18.99Exp: 2031-06-08→ Common Stock (3,199 underlying) - Sale
Common Stock
2024-09-10$49.05/sh−8,490$416,418→ 12,011 total - Exercise/Conversion
Stock Option (right to buy)
2024-09-10−10,000→ 0 totalExercise: $4.15Exp: 2032-06-07→ Common Stock (10,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-09-10−7,501→ 0 totalExercise: $18.99Exp: 2031-06-08→ Common Stock (7,501 underlying) - Exercise/Conversion
Common Stock
2024-09-10$18.99/sh+7,501$142,444→ 20,501 total - Exercise/Conversion
Common Stock
2024-09-09$18.99/sh+3,199$60,749→ 6,199 total - Exercise/Conversion
Common Stock
2024-09-10$4.15/sh+10,000$41,500→ 13,000 total - Sale
Common Stock
2024-09-10$50.60/sh−350$17,710→ 3,000 total - Sale
Common Stock
2024-09-09$50.04/sh−3,199$160,068→ 3,000 total - Sale
Common Stock
2024-09-10$50.20/sh−8,661$434,796→ 3,350 total
Footnotes (6)
- [F1]The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on May 13, 2024.
- [F2]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.00 to $50.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $48.53 to $49.52. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $49.54 to $50.50. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F5]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $50.55 to $50.71. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F6]The option is fully vested and exercisable.